University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial Search: "LIVER"



Treatment trials which apply specifically to your search:


0C-14-2

Trial Leaders:
David Quinn

An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (Egfr, Her2, Her3) Mutations or EGFR Gene Amplification

Treatment:
Chemotherapy: Systemic

0C-14-9

Trial Leaders:
Anthony El-Khoueiry

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD6738 in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Systemic

0C-15-2

Trial Leaders:
Jorge Nieva

GO40782 / An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Treatment:
Chemotherapy: Systemic

0C-16-6

Trial Leaders:
Anthony El-Khoueiry

PhI-87 Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-16-7

Trial Leaders:
Anthony El-Khoueiry

An Open-label, Dose-finding and Proof of Concept Study for Probody™ therapeutics (probody tx) in Subjects with Metastatic or Locally Advanced Unresectable Solid Tumors and/or Lymphomas

Treatment:
Immunotherapy
Other

0C-16-8

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers

Treatment:
Chemotherapy: Local

0C-17-1

Trial Leaders:
Anthony El-Khoueiry

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 skip mutations and c-Met Dysregulation Advance Solid Tumors

Treatment:
Other

0C-17-11

Trial Leaders:
Diana Hanna

Phase 1 trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers

Treatment:
Other

0C-17-14

Trial Leaders:
Anthony El-Khoueiry

An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following a Single Oral Dose in Patients with Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment

Treatment:
Chemotherapy: Systemic

0C-17-17

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 First-in-human Study of BMS-986258 Alone and in Combination with Nivolumab in Advanced Malignant Tumors

Treatment:
Immunotherapy

0C-17-2

Trial Leaders:
David Quinn

A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers

Treatment:
Biological Response Modifier
Chemotherapy: Systemic

0C-17-3

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-17-4

Trial Leaders:
Anthony El-Khoueiry

Phase 1b multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with mesothelin expressing advanced or recurrent malignancies

Treatment:
Biological Response Modifier

0C-17-5

Trial Leaders:
Heinz Josef Lenz

A Phase 1b/2 Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors

Treatment:
Biological Response Modifier
Chemotherapy: Systemic

0C-18-16

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Open-label, Multicenter Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects With Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy

Treatment:
Immunotherapy

0C-18-17

Trial Leaders:
Anthony El-Khoueiry

A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation

Treatment:
Chemotherapy: Systemic

0C-18-19

Trial Leaders:
Anthony El-Khoueiry

A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination with Atezolizumab in Patients with Specific HER2-Positive Advanced or Metastatic Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-18-2

Trial Leaders:
Anthony El-Khoueiry

A Phase I Study of FID-007 in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-18-21

Trial Leaders:
Diana Hanna

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.

Treatment:
Chemotherapy: Systemic
Immunotherapy

0C-18-22

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination with MGA012, an anti-PD-1 antibody, in Patients with Relapsed or Refractory B7-H3-Expressing Tumors

Treatment:
(No treatments specified)

0C-18-23

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms

Treatment:
Immunomodulator

0C-18-24

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176

Treatment:
Immunotherapy

0C-18-5

Trial Leaders:
Heinz Josef Lenz

An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 905677 administered intravenously in patients with advanced solid tumours

Treatment:
Chemotherapy: Systemic

0C-18-7

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

Treatment:
Chemotherapy: Systemic

0C-18-8

Trial Leaders:
Jorge Nieva

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors

Treatment:
Autologous Bone Marrow Transplant
Immunotherapy

0C-19-3

Trial Leaders:
Jacob Thomas

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

Treatment:
Immunotherapy

0C-19-4

Trial Leaders:
Anthony El-Khoueiry

Phase 1 Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Lorlatinib in Advanced Cancer Patients

Treatment:
Immunotherapy

0C-19-7

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti–CTLA-4 Monoclonal Antibody in Subjects With Advanced Cancer

Treatment:
Immunotherapy

0S-08-9

Trial Leaders:
David Quinn

Short-Term Fasting Prior to Platinum-Based Chemotherapy: Feasibility and Impact on Toxicity.

Treatment:
Chemotherapy: Systemic

0S-10-3

Trial Leaders:
David Quinn

A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy.

Treatment:
Other

0S-15-11

Trial Leaders:
David Quinn

PhI-81 A Phase 1 Study of (Cabozantinib) plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors

Treatment:
Other

0S-15-6

Trial Leaders:
David Quinn

A Pilot Study of Neoadjuvant sEphB4-HSA in Patients with Genitourinary Cancers

Treatment:
Anti-Angiogenesis

0S-16-13

Trial Leaders:
David Quinn

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

Treatment:
Chemotherapy: Systemic

0S-16-18

Trial Leaders:
Anthony El-Khoueiry

A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients with Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer

Treatment:
Chemotherapy: Systemic
Other

0S-16-8

Trial Leaders:
Jorge Nieva

A Phase IIa Trial of sEphB4-HSA in Combination with Anti PD-1 Antibody (Pembrolizumab, MK3475) in Patients with Non-Small Cell Lung and Head/Neck Cancer

Treatment:
Chemotherapy: Systemic

0S-17-3

Trial Leaders:
Julie Lang

Phase 2a Dose-Rising, Safety, Tolerability and Efficacy Study of Topical SOR007 for Cutaneous Metastases

Treatment:
Chemotherapy: Local

0S-18-1

Trial Leaders:
Anil Tulpule

A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies

Treatment:
Other

10M-17-4

Trial Leaders:
Gino In

A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma

Treatment:
Immunotherapy

10M-18-2

Trial Leaders:
Gino In

Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I only).

Treatment:
Chemotherapy: Systemic

11S-17-1

Trial Leaders:
James Hu

PhII-148 A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma

Treatment:
Biological Response Modifier

13NHL-17-1

Trial Leaders:
Kevin Kelly

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/ Refractory Indolent Non-Hodgkin Lymphoma (INHL)

Treatment:
Chemotherapy: Systemic
Other

18M-18-1

Trial Leaders:
Bing Xia

PhII-175: Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and MK-3475 (Pembrolizumab) Compared to MK-3475 (Pembrolizumab) Alone for Mesothelin-Positive Malignant Pleural Mesothelioma

Treatment:
Immunotherapy

1B-13-1

Trial Leaders:
Min Janice Lu

A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer

Treatment:
Chemotherapy: Systemic

1B-17-3

Trial Leaders:
Jason Ye

Prone Partial Breast Irradiation (PBI): Prospective Randomized Controlled Non-Inferiority Trial to Compare Radiation Fibrosis with Five versus Three Fractions

Treatment:
Radiation: External

1B-18-2

Trial Leaders:
Min Janice Lu

BYLieve: A phase II, multicenter, open-label, two-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment

Treatment:
Chemotherapy: Systemic

1B-18-4

Trial Leaders:
Min Janice Lu

A double-blind, placebo-controlled, randomized phase III study of Ipatasertib in combination with Paclitaxel as a treatment for patients with PIK3CA/AKT1/PTEN-altered, locally advanced or metastatic, triple-negative breast cancer or hormone receptor– positive, her2-negative breast cancer

Treatment:
Chemotherapy: Systemic

1B-19-2

Trial Leaders:
Min Janice Lu

Elacestrant Monotherapy vs Standard of Care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer Following CDK4/6 inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active Controlled, Multicenter Trial (EMERALD)

Treatment:
Chemotherapy: Systemic

2N-13-6

Trial Leaders:
Jorge Nieva

A Randomized Phase II Study of Epigenetic Priming with Azacitidine and Entinostat Prior to Nivolumab versus Nivolumab Alone in Subjects with Recurrent Metastatic Non-Small Cell Lung Cancer

Treatment:
Chemotherapy: Systemic

2N-16-9

Trial Leaders:
Thomas Chen

Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC)

Treatment:
Other

2N-17-1

Trial Leaders:
Jorge Nieva

PhII-156 A Phase II trial of AZD9291 (osimertinib) with or without bevacizumab in patients with EGFR mutation positive NSCLC and brain metastases

Treatment:
Anti-Angiogenesis
Biological Response Modifier

2N-17-2

Trial Leaders:
Jorge Nieva

A Phase III, Double-blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum based Chemotherapy in Patients with Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Treatment:
Chemotherapy: Systemic

2N-17-3

Trial Leaders:
Jorge Nieva

A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)

Treatment:
Chemotherapy: Systemic

2N-19-1

Trial Leaders:
Bing Xia

A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1)

Treatment:
Chemotherapy: Systemic
Immunotherapy

2N-19-2

Trial Leaders:
Jason Ye

A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)

Treatment:
Immunotherapy
Radiation: External

3A-15-1

Trial Leaders:
Syma Iqbal

PHII-133: Part A: A Multi-Institutional Phase II Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal. Part B: A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal

Treatment:
Immunotherapy

3C-17-3

Trial Leaders:
Afsaneh Barzi

A Phase I/II Study of Regorafenib and Pembrolizumab in Metastatic Colorectal Cancer Patients in 3rd and 4th line setting

Treatment:
Immunotherapy

3C-18-1

Trial Leaders:
Heinz Josef Lenz

A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced colorectal cancer

Treatment:
Chemotherapy: Systemic

3C-18-10

Trial Leaders:
Heinz Josef Lenz

A Randomized, Multicenter, Parallel-Group, Phase III Study To Compare The Efficacy Of Arfolitixorin Versus Leucovorin In Combination With 5-Fluorouracil, Oxaliplatin, And Bevacizumab In Patients With Advanced Colorectal Cancer

Treatment:
(No treatments specified)

3C-18-7

Trial Leaders:
Heinz Josef Lenz

A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects with Select Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic
Immunotherapy

3C-18-8

Trial Leaders:
Heinz Josef Lenz

Phase II, open-label, single arm, multicenter study of encorafenib, binimetinib plus cetuximab in subjects with previously untreated BRAF V600E -mutant Metastatic Colorectal Cancer

Treatment:
Chemotherapy: Systemic

3C-19-1

Trial Leaders:
Afsaneh Barzi

A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination with FOLFIRI and Bevacizumab for Second-Line Treatment of Metastatic Colorectal Cancer in Patients with a Kras Mutation

Treatment:
(No treatments specified)

3C-19-3

Trial Leaders:
Heinz Josef Lenz

PhII-186:A Phase 2 Study of Savolitinib in Subjects with MET Amplified Metastatic Colorectal Cancer

Treatment:
(No treatments specified)

3C-19-5

Trial Leaders:
Heinz Josef Lenz

Relapsed/Refractory Microsatellite-stable (MSS) Colorectal Cancer (CRC) Immunotherapy-naïve Subjects Treated with Tilsotolimod in Combination with Nivolumab and Ipilimumab (Cohort 3) Main Study:Study of Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors

Treatment:
Immunotherapy

3C-19-6

Trial Leaders:
Heinz Josef Lenz

An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety,Tolerability, and Anti-Tumor Activity of ATP128, with or without BI 754091, in Patients with Stage IV Colorectal Cancer

Treatment:
Immunotherapy
Vaccine

3E-17-3

Trial Leaders:
Syma Iqbal

A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma

Treatment:
Chemotherapy: Systemic
Immunotherapy

3E-18-1

Trial Leaders:
Syma Iqbal

A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the anti-PD-1 Antibody Tislelizumab (BGB-A317) versus Chemotherapy as Second Line Treatment in Patients with Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma

Treatment:
Chemotherapy: Systemic
Immunotherapy

3G-18-3

Trial Leaders:
Syma Iqbal

Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2 Expressing Gastroesophageal Adenocarcinoma (GEA)

Treatment:
Immunotherapy

3GB-14-1

Trial Leaders:
Anthony El-Khoueiry

A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy

Treatment:
Chemotherapy: Systemic

3L-17-1

Trial Leaders:
Anthony El-Khoueiry

A Phase I Open Label, Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRS Specific for Alpha Fetoprotein (AFPC332T) in HLA-A2 Positive Subjects with Advanced Hepatocellular Carcinoma (HCC)

Treatment:
Other

3L-17-5

Trial Leaders:
Anthony El-Khoueiry

A multicenter, non-randomized, open-label dose escalation Phase Ib study of regorafenib in combination with pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) with no prior systemic therapy.

Treatment:
Anti-Angiogenesis
Immunotherapy

3L-18-1

Trial Leaders:
Anthony El-Khoueiry

A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation

Treatment:
Immunotherapy

3L-18-2

Trial Leaders:
Anthony El-Khoueiry

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma

Treatment:
Chemotherapy: Systemic

3L-19-1

Trial Leaders:
Anthony El-Khoueiry

A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy

Treatment:
Immunotherapy

3P-18-2

Trial Leaders:
Diana Hanna

Phase 1/2 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GP-2250 in Combination with Gemcitabine in Subjects with Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma Who Have Progressed on Prior Treatment with FOLFIRINOX Chemotherapy

Treatment:
Chemotherapy: Systemic

3P-19-1

Trial Leaders:
Diana Hanna

A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer

Treatment:
Chemotherapy: Systemic
Immunotherapy

3P-19-2

Trial Leaders:
Syma Iqbal

A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas

Treatment:
Chemotherapy: Systemic

4B-14-2

Trial Leaders:
Hooman Djaladat

Prevention of parastomal hernia following radical cystectomy and ileal conduit using biologic mesh: Randomized Clinical Trial

Treatment:
Other

4B-15-11

Trial Leaders:
Sarmad Sadeghi

A Phase II Trial of sEphB4-HSA in Combination with Anti PD1 Antibody (Pembrolizumab, MK-3475) for Solid Tumors

Treatment:
Immunotherapy

4B-16-6

Trial Leaders:
Sarmad Sadeghi

PhII-135 A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma

Treatment:
Chemotherapy: Systemic

4B-16-8

Trial Leaders:
David Quinn

PhII-147 An Open Label, Multicenter, Single arm Phase II study to evaluate the Activity and Tolerability of the novel mTOR Inhibitor, MLN0128 (TAK-228), in patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the urothelial tract whose tumors harbor a TSC1 and/or a TSC2 mutation.

Treatment:
Chemotherapy: Systemic
Other

4B-17-2

Trial Leaders:
David Quinn

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy

Treatment:
Biological Response Modifier

4B-18-4

Trial Leaders:
Siamak Daneshmand

Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing

Treatment:
Chemotherapy: Systemic
Immunotherapy

4B-18-5

Trial Leaders:
David Quinn

PhII-176 A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects

Treatment:
Chemotherapy: Systemic

4B-19-2

Trial Leaders:
David Quinn

A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy

Treatment:
Biological Response Modifier
Immunotherapy

4K-16-5

Trial Leaders:
Sarmad Sadeghi

Phase II Randomized Double Blind Trial of PF 04518600, an OX40 Antibody, in Combination with Axitinib versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients with Metastatic Renal Cell Carcinoma

Treatment:
Immunotherapy

4K-18-2

Trial Leaders:
Haris Zahoor

A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma

Treatment:
Immunotherapy

4P-16-11

Trial Leaders:
Jacek Pinski

Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration- Resistant Prostate Cancer and DNA-Repair Anomalies

Treatment:
Other

4P-16-2

Trial Leaders:
David Quinn

Immune Activation and Cellular Response from Enzalutamide Alone or with Radium223 in Men with Metastatic, Castration-Resistant Prostate Cancer

Treatment:
Other

4P-17-2

Trial Leaders:
Mitchell Gross

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency

Treatment:
(No treatments specified)

4P-17-3

Trial Leaders:
Mitchell Gross

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency

Treatment:
Hormone
Other

4P-17-6

Trial Leaders:
Mitchell Gross

A phase IB open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprivation therapy and other agents in subjects with castrateresistant prostate cancer (CRPC)

Treatment:
Other

4P-18-2

Trial Leaders:
Monish Aron Monish

SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 multi-institution randomized prospective clinical trial evaluating the impact of cytoreductive radical prostatectomy combined with best systemic therapy on oncologic and quality of life outcomes in men with newly diagnosed metastatic prostate cancer

Treatment:
Chemotherapy: Systemic
Hormone
Surgery

4P-19-5

Trial Leaders:
David Quinn

A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (MK-3475-921) (KEYNOTE-921)

Treatment:
Chemotherapy: Systemic
Immunotherapy

4PE-16-1

Trial Leaders:
David Quinn

Phase II Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma following Previous Chemotherapy

Treatment:
Other

5C-17-2

Trial Leaders:
Koji Matsuo

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma

Treatment:
Chemotherapy: Systemic
Immunotherapy
Other

5C-19-1

Trial Leaders:
Koji Matsuo

A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects with Metastatic or Locally Advanced Solid Tumors, with Expansion to Select Solid Tumors

Treatment:
Immunotherapy

5GYN-16-1

Trial Leaders:
Koji Matsuo

PhI-86 Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vulvar Cancer

Treatment:
Chemotherapy: Systemic

5GYN-16-2

Trial Leaders:
Lynda Roman

A Two-Cohort Randomized Phase 2 Trial of the IRX 2 Regimen in Women with Squamous Cervical Intraepithelial Neoplasia 3 (CIN 3) or Vulvar Intraepithelial Neoplasia 3 (VIN 3)

Treatment:
Chemotherapy: Systemic

5O-18-1-GOG-3018

Trial Leaders:
Koji Matsuo

A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

Treatment:
Anti-Angiogenesis
Chemotherapy: Systemic

6B-17-1

Trial Leaders:
Naveed Wagle

A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy STELLAR Study

Treatment:
Chemotherapy: Systemic
Other

6G-15-2

Trial Leaders:
Naveed Wagle

An Open-Label, Phase 1/2a Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent Grade IV Glioma

Treatment:
Other

7H-17-1

Trial Leaders:
Jorge Nieva

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Treatment:
Immunotherapy
Vaccine

7H-17-2

Trial Leaders:
Jorge Nieva

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (MK3475-689) (Keynote 689) (LA HNSCC)

Treatment:
Chemotherapy: Systemic
Immunotherapy

7H-18-1

Trial Leaders:
Bing Xia

ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419) – Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer

Treatment:
Other

7H-18-2

Trial Leaders:
Bing Xia

Accuracy Study: A Phase 2, Open-Label, Single-Arm, Multi-Center Study of AL101 in Patients with Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations

Treatment:
Anti-Angiogenesis

9L-15-11

Trial Leaders:
Casey O'Connell

Clinical Study Protocol With Amendment 1 A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Treatment:
Chemotherapy: Systemic

9L-15-12

Trial Leaders:
Kevin Kelly

A Phase Ib/II Multi-Arm Study with Venetoclax in Combination with Cobimetinib and Venetoclax in Combination with Idasanutlin in Patients Aged =60 Years with Relapsed or Refractory Acute Myeloid Leukemia who Are Not Eligible for Cytotoxic Therapy

Treatment:
Other

9L-16-15

Trial Leaders:
Casey O'Connell

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination with Ruxolitinib in Subjects with Myelofibrosis

Treatment:
Chemotherapy: Systemic
Other

9L-16-3

Trial Leaders:
Casey O'Connell

A Phase I/II Multicenter Study Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patients with Intermediate or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Treatment:
Other

9L-17-13

Trial Leaders:
Kevin Kelly

PhI-92: (NCI 10075) A Phase 1B Study of AMG-232 in Combination with Decitabine in Acute Myeloid Leukemia

Treatment:
Chemotherapy: Systemic

9L-17-6

Trial Leaders:
Kevin Kelly

Phase 1b/II Study of Escalating Doses of Pevonedistat (Tak-924, Formerly Mln4924) Administered in Combination with Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myelogenous Leukemia (AML)

Treatment:
Chemotherapy: Systemic

9L-18-13

Trial Leaders:
Casey O'Connell

PhII-171/ NCI 10147: A Phase II Randomized Study of Topotecan/Carboplatin with or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML)

Treatment:
Chemotherapy: Systemic

9L-18-14

Trial Leaders:
Casey O'Connell

An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed Ruxolitinib

Treatment:
Chemotherapy: Systemic

9L-18-15

Trial Leaders:
Casey O'Connell

A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Treatment:
Chemotherapy: Systemic

9L-18-18

Trial Leaders:
George Yaghmour

A Phase 4, open-label, randomized study of two Inotuzumab Ozogamicin dose levels in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia eligible for hematopoietic stem cell transplantation and who have risk factor(s) for veno-occlusive disease

Treatment:
(No treatments specified)

9L-18-7

Trial Leaders:
George Yaghmour

A Phase 1 Dose Escalation Trial of SKI-G-801 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Treatment:
(No treatments specified)

9L-18-9

Trial Leaders:
George Yaghmour

A Phase 2 Study of Ibrutinib and Blinatumomab in Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia

Treatment:
Chemotherapy: Systemic

CTSU- A021502

Trial Leaders:
Heinz Josef Lenz

Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

Treatment:
Chemotherapy: Systemic

CTSU-A031102

Trial Leaders:
James Hu

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy using Mobilizing Paclitaxel plus Ifosfamide followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors

Treatment:
Chemotherapy: Systemic

CTSU-A031501

Trial Leaders:
David Quinn

Phase III randomized “Adjuvant study of MK-3475 (pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma” (AMBASSADOR) versus observation

Treatment:
Immunotherapy

CTSU-A081105

Trial Leaders:
Jorge Nieva

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Treatment:
Chemotherapy: Systemic

CTSU-A221504

Trial Leaders:
Jorge Nieva

A Randomized, Double-Blind, Placebo-Controlled Pilot Study Of An Oral, Selective Peripheral Opioid Receptor Antagonist In Advanced Non-Small Cell Lung Cancer

Treatment:
Other

CTSU-A221505

Trial Leaders:
Naomi Schechter

Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction

Treatment:
Radiation: External

CTSU-AGCT1531

Trial Leaders:
Anishka D'Souza

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Treatment:
Chemotherapy: Systemic

CTSU-AGCT1532

Trial Leaders:
Anishka D'Souza

A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumors

Treatment:
Chemotherapy: Systemic

CTSU-E4512

Trial Leaders:
Jorge Nieva

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Treatment:
Chemotherapy: Systemic

CTSU-EA2165

Trial Leaders:
Syma Iqbal

A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

Treatment:
Chemotherapy: Systemic
Immunotherapy

CTSU-EA6174

Trial Leaders:
Gino In

Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

Treatment:
Immunotherapy

CTSU-EA8134

Trial Leaders:
Anne Schuckman

International Penile Advanced Cancer Trial

Treatment:
Chemotherapy: Systemic
Surgery

CTSU-EAY131

Trial Leaders:
Heinz Josef Lenz

Molecular Analysis for Therapy Choice (MATCH)

Treatment:
(No treatments specified)

CTSU/NRG-CC003

Trial Leaders:
Richard Jennelle

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

Treatment:
Radiation: External

CTSU/NRG-LU002

Trial Leaders:
Jason Ye

Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

Treatment:
Radiation: External

ctsu/NSABP-51/RTOG1304

Trial Leaders:
Naomi Schechter

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Treatment:
Radiation: External

CTSU/RTOG1112

Trial Leaders:
Anthony El-Khoueiry

Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

Treatment:
Chemotherapy: Systemic
Radiation: External

NC-HEM-19-2

Trial Leaders:
Howard Liebman

A phase II, open-label, prospective, single-arm, study to assess ability of eltrombopag to induce sustained remission in subjects with ITP who are refractory or relapsed after first-line steroids (TAPER)

Treatment:
(No treatments specified)

NRG-BN003

Trial Leaders:
Eric Chang

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

Treatment:
Other

NRG-GU005

Trial Leaders:
Leslie Ballas

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for localized intermediate risk prostate cancer

Treatment:
Radiation: External

NRG-GU006

Trial Leaders:
Leslie Ballas

A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer

Treatment:
Hormone
Radiation: External

RTOG-1008

Trial Leaders:
Richard Jennelle

A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors.

Treatment:
Chemotherapy: Systemic
Radiation: External

SWOG-S0820

Trial Leaders:
Syma Iqbal

A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES).

Treatment:
Other

SWOG-S1418-BR006

Trial Leaders:
Min Janice Lu

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy.

Treatment:
Chemotherapy: Systemic

SWOG-S1500

Trial Leaders:
David Quinn

A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma

Treatment:
Other

SWOG-S1501

Trial Leaders:
Irene Kang

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III

Treatment:
Other

SWOG-S1512

Trial Leaders:
Gino In

A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unsectable Desmoplastic Melanoma (DM)

Treatment:
Other

SWOG-S1607

Trial Leaders:
Gino In

A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (pembrolizumab) (NSC-776864) in Patients with Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy

Treatment:
Immunotherapy

SWOG-S1609

Trial Leaders:
Heinz Josef Lenz

DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors

Treatment:
Immunotherapy

SWOG-S1801

Trial Leaders:
Gino In

A phase II randomized study of adjuvant versus neoadjuvant MK-3475 (pembrolizumab) for clinically detectable stage III-IV high risk melanoma

Treatment:
Other

SWOG-S1802

Trial Leaders:
Siamak Daneshmand

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Treatment:
Chemotherapy: Systemic
Hormone

SWOG-S1806

Trial Leaders:
Leslie Ballas

Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer

Treatment:
Chemotherapy: Systemic
Immunotherapy

SWOG-S1815

Trial Leaders:
Anthony El-Khoueiry

A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Treatment:
Chemotherapy: Systemic

Phase I trials for all solid tumors:


0C-14-9

Trial Leaders:
Anthony El-Khoueiry

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD6738 in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Systemic

0C-16-6

Trial Leaders:
Anthony El-Khoueiry

PhI-87 Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-16-7

Trial Leaders:
Anthony El-Khoueiry

An Open-label, Dose-finding and Proof of Concept Study for Probody™ therapeutics (probody tx) in Subjects with Metastatic or Locally Advanced Unresectable Solid Tumors and/or Lymphomas

Treatment:
Immunotherapy
Other

0C-16-8

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers

Treatment:
Chemotherapy: Local

0C-17-1

Trial Leaders:
Anthony El-Khoueiry

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 skip mutations and c-Met Dysregulation Advance Solid Tumors

Treatment:
Other

0C-17-11

Trial Leaders:
Diana Hanna

Phase 1 trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers

Treatment:
Other

0C-17-14

Trial Leaders:
Anthony El-Khoueiry

An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following a Single Oral Dose in Patients with Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment

Treatment:
Chemotherapy: Systemic

0C-17-17

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 First-in-human Study of BMS-986258 Alone and in Combination with Nivolumab in Advanced Malignant Tumors

Treatment:
Immunotherapy

0C-17-2

Trial Leaders:
David Quinn

A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers

Treatment:
Biological Response Modifier
Chemotherapy: Systemic

0C-17-3

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-17-4

Trial Leaders:
Anthony El-Khoueiry

Phase 1b multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with mesothelin expressing advanced or recurrent malignancies

Treatment:
Biological Response Modifier

0C-18-16

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Open-label, Multicenter Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects With Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy

Treatment:
Immunotherapy

0C-18-17

Trial Leaders:
Anthony El-Khoueiry

A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation

Treatment:
Chemotherapy: Systemic

0C-18-19

Trial Leaders:
Anthony El-Khoueiry

A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination with Atezolizumab in Patients with Specific HER2-Positive Advanced or Metastatic Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-18-2

Trial Leaders:
Anthony El-Khoueiry

A Phase I Study of FID-007 in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-18-21

Trial Leaders:
Diana Hanna

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.

Treatment:
Chemotherapy: Systemic
Immunotherapy

0C-18-22

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination with MGA012, an anti-PD-1 antibody, in Patients with Relapsed or Refractory B7-H3-Expressing Tumors

Treatment:
(No treatments specified)

0C-18-23

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms

Treatment:
Immunomodulator

0C-18-24

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176

Treatment:
Immunotherapy

0C-18-5

Trial Leaders:
Heinz Josef Lenz

An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 905677 administered intravenously in patients with advanced solid tumours

Treatment:
Chemotherapy: Systemic

0C-18-7

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

Treatment:
Chemotherapy: Systemic

0C-19-3

Trial Leaders:
Jacob Thomas

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

Treatment:
Immunotherapy

0C-19-4

Trial Leaders:
Anthony El-Khoueiry

Phase 1 Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Lorlatinib in Advanced Cancer Patients

Treatment:
Immunotherapy

0C-19-7

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti–CTLA-4 Monoclonal Antibody in Subjects With Advanced Cancer

Treatment:
Immunotherapy

0S-08-9

Trial Leaders:
David Quinn

Short-Term Fasting Prior to Platinum-Based Chemotherapy: Feasibility and Impact on Toxicity.

Treatment:
Chemotherapy: Systemic

CTSU-EAY131

Trial Leaders:
Heinz Josef Lenz

Molecular Analysis for Therapy Choice (MATCH)

Treatment:
(No treatments specified)




Trials which are NOT treatments of disease. Specimens or information may be collected:


0S-04-7

Trial Leaders:
Michael Press

USC Tumor and Tissue Bank.


0S-11-5

Trial Leaders:
Amir Goldkorn

Circulating Tumor Cell Collection from Cancer Patients.


0S-12-4

Trial Leaders:
Stephen Gruber

USC Norris Comprehensive Cancer Center - Cancer Genetics Registry.


0S-15-12

Trial Leaders:
Stephen Gruber

Norris ORIEN Total Cancer Care Protocol: A Lifetime Partnership with Patients.


0S-15-16

Trial Leaders:
Akil Merchant

Protocol for Immunology Specimen Collection from Cancer Patients, Patients with Hematologic Diagnoses, and Healthy Normal Controls


0S-15-7

Trial Leaders:
Semara Thomas

Long Term Effects of Tyrosine Kinase Inhibitors on Ovarian Reserve and Fertility-A pilot study,A Pilot Study


0S-16-1

Trial Leaders:
Shannon Mumenthaler

Characterization of Mechanical Tissue Properties in Pancreas, Liver and Colon


0S-16-9

Trial Leaders:
Ebrahim Zandi

The Role of Microbiome in Cancer Therapy


0S-18-5

Trial Leaders:
Darcy Spicer

Improving Patient Access to Cancer Clinical Trials ( iMPACT Study)


0S-18-8

Trial Leaders:
Jorge Nieva

Precision Performance Status Assessment in Early Phase Clinical Trials


0S-99-10

Trial Leaders:
Heinz Josef Lenz

Blood Collection in Patients with GI Cancer and Patients Undergoing Endoscopy


16M-18-2

Trial Leaders:
Leslie Ballas

Phase II Multi-Institutional Study of Low-Dose (2Gy x 2) Palliative Radiotherapy in the Treatment of Symptomatic Bone metastases from Multiple Myeloma


1B-11-1

Trial Leaders:
Julie Lang

Breast Cancer Blood Biorepository.


1B-12-6

Trial Leaders:
Jaques Van Dam

Light-Scattering Spectroscopy for the Detection of Stage II-III Breast Cancer: A Pilot Study.


1B-13-2

Trial Leaders:
Julie Lang

Core Biopsies of Breast Tumor Tissue Repository.


1B-16-3

Trial Leaders:
Mary W. Yamashita

Emerging Tools in the Detection of Breast Cancer: Comparison of Contrast Enhanced Spectral Mammography with Digital Breast Tomosynthesis to Conventional Imaging Techniques Including Contrast Enhanced Magnetic Resonance Imaging and 2D Mammography with or without Targeted Ultrasound


1B-16-5

Trial Leaders:
Stephen Gruber

Trial of Strategies to Communicate Genetic Information to Different Ethnic and Racial Subpopulations


1B-16-7

Trial Leaders:
Min Janice Lu

Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Advanced Breast Cancer


1B-17-1

Trial Leaders:
Julie Lang

Combined Breast MRI/Biomarker Strategies to Identify Aggressive Biology


2L-17-1

Trial Leaders:
Pamela Ward

Liquid Biopsy Research Project


2N-16-1

Trial Leaders:
Christopher Lee

Dynamic Perfusion Computed Tomography Changes after Stereotactic Body Radiation Therapy for Localized Non-Small Cell Lung Cancer


3C-18-2

Trial Leaders:
Afsaneh Barzi

Detection of Microsatellite Instability in circulating tumor DNA of patients with stage IV Colorectal Carcinoma


3C-19-4

Trial Leaders:
Kimberly  Miller

Colorectal Cancer in Adolescents and Young Adults: A Pilot Study of Medical and Psychosocial Issues


3G-07-3

Trial Leaders:
Heinz Josef Lenz

Establishing Continuous Cell Lines and Xenografts from Adult Malignant Solid Tumors and Inflammatory Bowel Disease for Biological and Pre-Clinical Therapeutic Studies.


3L-17-4

Trial Leaders:
Syma Iqbal

A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma


4B-13-1

Trial Leaders:
Siamak Daneshmand

4B-13-1: Blue Light Cystoscopy™ with Cysview® Registry


4B-15-2

Trial Leaders:
Jacek Pinski

MDSC Clinical Assay for Cancer Detection And Monitoring in Bladder Carcinoma


4B-16-2

Trial Leaders:
David Quinn

UC-GENOME: Urothelial Cancer-GENOmic analysis to iMprove patient outcomes and rEsearch


4K-03-2

Trial Leaders:
Eila Skinner

Kidney Cancer Data and Specimen Collection Project.


4K-14-4

Trial Leaders:
Jacek Pinski

MDSC Clinical Assay for Cancer Detection and Monitoring in Renal Cell Carcinoma


4P-01-2

Trial Leaders:
Eila Skinner

Prostate Cancer Prostatectomy Data and Specimen Collection Project.


4P-11-4

Trial Leaders:
Mitchell Gross

Multi-Dimensional Assessment of Circulating Tumor Cells in Patients Treated For Metastatic Prostate Cancer.


4P-12-3

Trial Leaders:
Alan Epstein

MDSC Clinical Assay for Cancer Detection and Monitoring in Prostate Cancer.


4P-15-4

Trial Leaders:
Jacek Pinski

Studies of Cell-Free DNA and RNA in Blood from Patients Being Treated for Prostate Cancer


4P-16-7

Trial Leaders:
Inderbir Gill

Diagnosing Clinically Significant Prostate Cancer in African American and White Men Phase II, Randomized Clinical Trial, Multi-Center, MR-guided vs. 12-core Systematic Random Biopsy, Localized Prostate Cancer


4P-17-4

Trial Leaders:
Siamak Daneshmand

Prospective Validation of Prostate Biomarkers for Repeat Biopsy: The PRIORITY Study


5GYN-10-3

Trial Leaders:
Lynda Roman

Banking Tissues from Normal and Disease-Related Gynecologic Surgeries.


6CNS-07-1

Trial Leaders:
Thomas Chen

Establishment of USC CNS and Spine Tumor Bank.


7H-16-2

Trial Leaders:
Mark Shiroishi

A Pilot Study of Whole-Neck CT Perfusion with the Toshiba Aquilion One Vision-320 Detector Row CT Scanner For Use In Head & Neck Tumor Patients


9L-10-3

Trial Leaders:
Preet Chaudhary

Comprehensive Hematology Tissue Repository (BANK).


9L-16-10

Trial Leaders:
Houda Alachkar

Characterization of T-cell Repertoire in Patients with AML undergoing HSCT through Next-Generation Sequencing of TCRA and TCRB Genes


9L-17-16

Trial Leaders:
Houda Alachkar

Pharmacogenomics of age-specific, Asparaginase-induced hepatotoxicity in patients with Acute Lymphoblastic Leukemia


CTSU-EA1151

Trial Leaders:
Linda Hovanessian

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)


CTSU-EAF151

Trial Leaders:
Mark Shiroishi

Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma


NC-HEM-05-4

Trial Leaders:
Casey O'Connell

Hematology Database


NC-HEM-18-5

Trial Leaders:
Caroline Piatek

A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label, Pharmacokinetic, Noninferiority Study of Ravulizumab Administered Subcutaneously Versus Intravenously in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With Eculizumab


NC-HEM-19-4

Trial Leaders:
Caroline Piatek

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia


SWOG-S1703

Trial Leaders:
Irene Kang

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer